British pharmaceutical group AstraZeneca has held talks with US rival Bristol Myers Squibb about a merger valued at nearly $400 billion, The Financial Times reported Monday, citing unnamed sources. The deal would be one of the largest in the industry, though the talks are described as preliminary.
According to a report by The Financial Times, British pharmaceutical giant AstraZeneca has held preliminary merger talks with U.S. rival Bristol Myers Squibb. The potential deal, valued at nearly $400 billion, would be one of the largest pharmaceutical mergers in history. No formal offer has been made, and the talks are described as early-stage. The report cites unnamed sources familiar with the matter. Neither company has commented publicly.
- DevelopingMusk pushes $60 billion stock merger deal to combine SpaceX and xAI
- DevelopingSpaceX market value nears $3 trillion amid continued rally
- DevelopingTSMC to invest additional $100 billion in Arizona, chairman says
- DevelopingParamount-Warner Bros merger frozen until antitrust trial concludes, companies agree
Source and signal
A single-sourced dispatch is never rated Confirmed or Strong. Its Signal strengthens only when a second, independent source corroborates it.
- Open-source intake